Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 69

Sort by

Sort Order Select

Journal Articles

Disparities in Time to First Prescription Fill for Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma

Hamlet Gasoyan, Faiz Anwer, Jeffrey D. Kovach, Nicholas J Casacchia, Ming Wang, Jason Valent, Michael B. Rothberg

Blood (2024) 144 (Supplement 1): 5032.

https://doi.org/10.1182/blood-2024-201654

Published: 2024

Journal Articles

Epidemiological Trends in Incidence, Death and Associated Risk Factors of Multiple Myeloma 1990-2021 and Projection to 2040

Rupayan Kundu, Niladri Kal, Abhay Singh, Louis Williams, Jack Khouri, Christy J. Samaras, Jason Valent, Shahzad Raza, Willem Van Heeckeren, Faiz Anwer, Sandra Mazzoni

Blood (2024) 144 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2024-211861

Published: 2024

Journal Articles

A Pilot Screening and Patient Navigation Program for Early Detection of Multiple Myeloma to Address Cancer Disparities

Diana Basali, Heather McKee Hurwitz, Kim Bell, Kimberly Sanders, Mark Ribbins, Raymond Jackson, Jason Valent

Blood (2024) 144 (Supplement 1): 5167.

https://doi.org/10.1182/blood-2024-210614

Published: 2024

Journal Articles

Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy

John Hanna, Ryan Brown, Zain Ali Burney, Kawther Abdallah, Jason Valent, Christy J. Samaras, Faiz Anwer, Jack Khouri, Louis Williams, Shahzad Raza, Willem Van Heeckeren, Sandra Mazzoni

Blood (2024) 144 (Supplement 1): 1911.

https://doi.org/10.1182/blood-2024-208479

Published: 2024

Journal Articles

Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients

Louis Williams, Danai Dima, Hanny Sawaf, Ali Mehdi, Daniel Cancilla, Hira Shaikh, Faiz Anwer, Sandra Mazzoni, Beth M. Faiman, Jack Khouri, Christy J. Samaras, Jason Valent, Shahzad Raza

Blood (2024) 144 (Supplement 1): 1918.

https://doi.org/10.1182/blood-2024-210799

Published: 2024

Journal Articles

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Blood (2024) 144 (Supplement 1): 891.

https://doi.org/10.1182/blood-2024-205077

Published: 2024

Journal Articles

Impact of T-Cell Redirecting Therapies on Survival Outcomes in Ultra-High-Risk Multiple Myeloma and Plasma Cell Leukemia

Hassan Elmaleh, Hong Li, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Beth M. Faiman, Jack Khouri, Jason Valent, Faiz Anwer, Louis S Williams

Blood (2024) 144 (Supplement 1): 7092.

https://doi.org/10.1182/blood-2024-208780

Published: 2024

Journal Articles

Improving Specialty Access for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): 10 Years of Experience and a Successful Model of Care

Beth M. Faiman, Louis S Williams, Jack Khouri, Faiz Anwer, Shahzad Raza, Christy J. Samaras, Kimberly Hamilton, Cynthia Scott, Saveta Mathur, Omer N. Koc, Willem J. van Heeckeren, Jason Valent, Sandra Mazzoni

Blood (2024) 144 (Supplement 1): 5170.8.

https://doi.org/10.1182/blood-2024-212088

Published: 2024

Journal Articles

US Physicians' Perspective and Practice Patterns for the Management of Transplant-Eligible-Newly Diagnosed Multiple Myeloma

Yara Shatnawi, Zainab Motiwala, Faiz Anwer, Danai Dima, Louis S Williams, Nausheen Ahmed, Sandra Mazzoni, Jack Khouri, Joslyn Rudoni, Mikhaila Rice, Diana Basali, Christy J. Samaras, Jason Valent, Al-Ola Abdallah, Tara Roy, Beth M. Faiman, Shahzad Raza

Blood (2024) 144 (Supplement 1): 7044.

https://doi.org/10.1182/blood-2024-212202

Published: 2024

Journal Articles

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

David Kaplan, Eric Christian, Jason Valent, Faiz Anwer, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Louis S. Williams, Danai Dima, Kelly Shepherd, Jared Fennema, Sherry Fada, Megan Nakashima, Mazen Hanna, Hillard M. Lazarus, Jack Khouri

Blood (2023) 142 (Supplement 1): 5031.

https://doi.org/10.1182/blood-2023-180735

Published: 2023

Journal Articles

Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

James A Davis, Danai Dima, Nausheen Ahmed, Shaun DeJarnette, Joseph P McGuirk, Jack Khouri, Jason Valent, Faiz Anwer, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2023-179981

Published: 2023

Journal Articles

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Mark Orland, Danai Dima, Fauzia Ullah, Hussein Awada, Diana Basali, Beth M. Faiman, Cynthia Scott, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Shahzad Raza, Jack Khouri

Blood (2023) 142 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2023-183030

Published: 2023

Journal Articles

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Blood (2023) 142 (Supplement 1): 7245.

https://doi.org/10.1182/blood-2023-190304

Published: 2023

Journal Articles

Association of Patient Characteristics and Insurance Type with Multiple Myeloma Care Patterns

Hamlet Gasoyan, Faiz Anwer, Nicholas J Casacchia, Jeff Kovach, Jason Valent, Michael B. Rothberg

Blood (2023) 142 (Supplement 1): 7388.

https://doi.org/10.1182/blood-2023-182003

Published: 2023

Journal Articles

An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma

Louis S. Williams, Bardia Khosravi, Marko Velimirovic, Jack Khouri, Shahzad Raza, Sandra Mazzoni, Christy J. Samaras, Hussein Awada, Danai Dima, Jason Valent, Faiz Anwer

Blood (2023) 142 (Supplement 1): 1990.

https://doi.org/10.1182/blood-2023-188762

Published: 2023

Journal Articles

Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study

Danai Dima, Aishwarya Sannareddy, Nausheen Ahmed, James A Davis, Hira Shaikh, Zahra Mahmoudjafari, Marissa Duco, Jack Khouri, Gurbakhash Kaur, Jonathan Lochner, Faiz Anwer, Aimaz Afrough, Jason Valent, Hamza Hashmi, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2023-180458

Published: 2023

Journal Articles

Impact of Prior Lines of Therapy before Autologous Hematopoietic Cell Transplant on Survival in Standard Risk Multiple Myeloma

Hussein Awada, Ali Hajj Ali, Danai Dima, Craig S Sauter, Louis Williams, Jack Khouri, Shahzad Raza, Sandra Mazzoni, Jason Valent, Christy J. Samaras, Faiz Anwer

Blood (2023) 142 (Supplement 1): 7069.

https://doi.org/10.1182/blood-2023-189995

Published: 2023

Journal Articles

Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Danai Dima, James A Davis, Nausheen Ahmed, Aishwarya Sannareddy, Hira Shaikh, Zahra Mahmoudjafari, Jack Khouri, Gurbakhash Kaur, Christopher Strouse, Jason Valent, Larry D. Anderson, Jr., Faiz Anwer, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 91.

https://doi.org/10.1182/blood-2023-180421

Published: 2023

Journal Articles

Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study

Jason Valent, Michaela Liedtke, Jeffrey A. Zonder, Richa Manwani, Chandrasekhar Udata, Juliana Ianus, John Tripptree, Julia Catini, Candida Cristina Quarta

Blood (2023) 142 (Supplement 1): 540.

https://doi.org/10.1182/blood-2023-186515

Published: 2023

Journal Articles

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Danai Dima, Fauzia Ullah, Serhan Unlu, Diana Basali, Mahir Khan, Abdullah Saeed Khan, Xuefei Jia, Majid Jaberi-Douraki, Beth M. Faiman, Sandra Mazzoni, Louis S. Williams, Christy J. Samaras, Jason Valent, Faiz Anwer, Jack Khouri, Shahzad Raza

Blood (2023) 142 (Supplement 1): 3407.

https://doi.org/10.1182/blood-2023-181365

Published: 2023

NARROW

Disparities in Time to First Prescription Fill for Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma

Epidemiological Trends in Incidence, Death and Associated Risk Factors of Multiple Myeloma 1990-2021 and Projection to 2040

A Pilot Screening and Patient Navigation Program for Early Detection of Multiple Myeloma to Address Cancer Disparities

Assessing the Efficacy and Safety of Reduced Dexamethasone Duration in Newly Diagnosed AL Amyloidosis Versus Standard Therapy

Current Management of Non-Amyloidosis Monoclonal Gammopathy of Renal Significance: Clinical Features, Treatment Selection, Response, and Renal Outcomes in a Recently Treated Patients

Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study

Impact of T-Cell Redirecting Therapies on Survival Outcomes in Ultra-High-Risk Multiple Myeloma and Plasma Cell Leukemia

Improving Specialty Access for Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) and Plasma Cell Disorders (PCDs): 10 Years of Experience and a Successful Model of Care

US Physicians' Perspective and Practice Patterns for the Management of Transplant-Eligible-Newly Diagnosed Multiple Myeloma

Molecular Expression Differences in Blood Mononuclear Cells in Patients with AL Amyloidosis

Impact of Frailty on Outcomes after CAR T-Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma

Outcomes of Venetoclax-Based Therapy in Patients with Daratumumab-Refractory t(11;14) Positive Light Chain Amyloidosis

Outcomes of Lymphoma and Multiple Myeloma Patients Following Inpatient Antineoplastic Treatment

Association of Patient Characteristics and Insurance Type with Multiple Myeloma Care Patterns

An Ensemble Machine Learning Model Using Gradient Boosting Identifies Patients with Disease Progression in Newly Diagnosed Multiple Myeloma

Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study

Impact of Prior Lines of Therapy before Autologous Hematopoietic Cell Transplant on Survival in Standard Risk Multiple Myeloma

Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Safety and Tolerability of Cael-101, an Anti-Amyloid Monoclonal Antibody, Combined with Anti-Plasma Cell Dyscrasia Therapy in Patients with Light-Chain Amyloidosis: 24-Month Results of a Phase 2 Study

Insights into Presentation and Outcomes of Localized Immunoglobulin Light Chain Amyloidosis: A 12-Year Experience of a Large Academic Center

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only